Blue Cross Blue Shield of North Dakota (BCBSND) wants to inform providers that on July 1, 2023, new biosimilars for Humira™ (adalimumab) were added to Blue Cross Blue Shield of North Dakota (BCBSND) commercial formularies. There will be no changes in coverage of Humira products. Currently, BCBSND covers Humira as a preferred product. Starting July 1, 2023, coverage of specific biosimilars Amjevita™ (NDCs beginning with 55513) and Hadlima™ will be added as additional preferred options.
If you have additional questions, contact the BCBSND Provider Service Center at 1-800-368-2312.